Wave Life Sciences (WVE) Downgraded by BidaskClub
BidaskClub cut shares of Wave Life Sciences (NASDAQ:WVE) from a buy rating to a hold rating in a research report released on Thursday.
Other equities analysts have also issued reports about the company. Mizuho set a $34.00 price objective on Wave Life Sciences and gave the company a buy rating in a research report on Saturday, October 21st. TheStreet raised Wave Life Sciences from a d+ rating to a c- rating in a research report on Friday, January 5th. Zacks Investment Research raised Wave Life Sciences from a sell rating to a hold rating in a research report on Thursday, October 12th. Finally, Leerink Swann reaffirmed an outperform rating and set a $53.00 price target (up previously from $42.00) on shares of Wave Life Sciences in a research report on Wednesday, November 15th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. Wave Life Sciences presently has an average rating of Hold and an average price target of $41.60.
Wave Life Sciences (NASDAQ:WVE) opened at $39.20 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.50 and a quick ratio of 11.50. Wave Life Sciences has a 12-month low of $15.15 and a 12-month high of $42.05. The stock has a market capitalization of $1,060.00 and a P/E ratio of -11.07.
In other news, insider Chandra Vargeese sold 2,000 shares of the stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $40.00, for a total value of $80,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ra Capital Management, Llc acquired 423,398 shares of the business’s stock in a transaction dated Tuesday, November 14th. The stock was bought at an average cost of $23.34 per share, with a total value of $9,882,109.32. The disclosure for this purchase can be found here. Corporate insiders own 53.00% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nationwide Fund Advisors boosted its holdings in shares of Wave Life Sciences by 58.1% in the 2nd quarter. Nationwide Fund Advisors now owns 6,720 shares of the company’s stock valued at $125,000 after buying an additional 2,470 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Wave Life Sciences by 71.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 9,422 shares of the company’s stock valued at $175,000 after buying an additional 3,912 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of Wave Life Sciences by 62.3% in the 2nd quarter. Rhumbline Advisers now owns 12,502 shares of the company’s stock valued at $233,000 after buying an additional 4,800 shares during the last quarter. Alliancebernstein L.P. acquired a new stake in shares of Wave Life Sciences in the 2nd quarter valued at approximately $236,000. Finally, New York State Common Retirement Fund boosted its holdings in shares of Wave Life Sciences by 64.9% in the 2nd quarter. New York State Common Retirement Fund now owns 12,700 shares of the company’s stock valued at $236,000 after buying an additional 4,999 shares during the last quarter. 73.80% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Wave Life Sciences (WVE) Downgraded by BidaskClub” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/wave-life-sciences-wve-downgraded-by-bidaskclub/1843740.html.
About Wave Life Sciences
WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.